Read by QxMD icon Read


Heinz Ludwig, Pere Gascón, Carsten Bokemeyer, Matti Aapro, Mario Boccadoro, Kris Denhaerynck, Andriy Krendyukov, Karen MacDonald, Ivo Abraham
PURPOSE: Granulocyte colony-stimulating factors (G-CSFs) are indicated for prophylaxis or management of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Guidelines recommend G-CSF 24-72 h following chemotherapy; however, some evidence suggests that G-CSF initiated < 24 h may benefit some patients. METHODS: MONITOR-GCSF was a prospective, observational, multicenter, pan-European study of 1447 chemotherapy-treated patients receiving daily biosimilar (standard) filgrastim (Zarzio®/Zarxio®, filgrastim-sndz, Hexal AG, Sandoz Inc...
October 20, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Badereddin Mohamad Al-Ali, Klaus Eredics, Stephan Madersbacher, Ingrid Schauer
OBJECTIVE: To analyze drug adherence, overall survival (OS) and hospitalization rates of patients with castration-resistant prostate cancer (CRPC) treated with arbiraterone acetate (AA), enzalutamide (ENZ) and their sequence in a real-life setting. METHODS: The database of the largest public insurance company in Austria was analyzed. All CRPC patients with at least one prescription of AA and/or ENZ between September 2013 and August 2016 in the pre-chemotherapy and post-chemotherapy setting were extracted and matched to the Austrian death and hospital admission statistics...
October 15, 2018: Wiener Klinische Wochenschrift
Ayesha Saba, Rozilla Sadia Khan, Humera Ismail
Growing teratoma syndrome (GTS) is a rare complication of ovarian germ cell tumours and occurs in young age group. It is characterized by clinical or radiological increase in tumour size during or after chemotherapy, with normalization of tumour marker levels. Histopathological tissue growth post chemotherapy is a mature teratoma without any malignant component. Mainstay of treatment is surgical excision of the disease to prevent progression of tumour as mature teratomas are resistant to both chemotherapy and radiotherapy...
June 2018: JPMA. the Journal of the Pakistan Medical Association
Myung-Sang Moon, Sang-Jae Kim, Min-Su Kim, Dong-Suk Kim
Study Design: A case study. Purpose: To assess the chronological changes of the disease-related kyphosis after chemotherapy alone, secondly to clarify the role of growth cartilage in the healed lesion on kyphosis change, and to define the accurate prediction time in assessing residual kyphosis. Overview of Literature: None of the previous papers up to now dealt with the residual kyphosis, stability and remodeling processes of the affected segments...
October 16, 2018: Asian Spine Journal
Hyerim Ha, Ju-Hee Bang, Ah-Rong Nam, Ji-Eun Park, Mei Hua Jin, Yung-Jue Bang, Do-Youn Oh
Purpose: The soluble programmed death-ligand 1 (sPDL1) has immunosuppressive activity and is a candidate biomarker for immuno-oncology drug development. In this study, we measured sPDL1 at pre-and post-chemotherapy and at disease progression to uncover the dynamics of sPDL1 during treatment in biliary tract cancer (BTC) patients. Materials and Methods: From 90 BTC patients (training cohort, 53; validation cohort, 37) who were candidates for palliative first-line chemotherapy, blood was collected at pre-and post-chemotherapy (at the time of best response) and at disease progression...
October 5, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
Hyun-Ah Kim, Jihye Choi, Chan Su Park, Min-Ki Seong, Sung-Eun Hong, Jae-Sung Kim, In-Chul Park, Jin Kyung Lee, Woo Chul Noh
In the era of precision medicine, the prediction of ovarian function recovery from chemotherapy-induced amenorrhoea using feasible biological markers may be helpful to optimise the treatment strategy for young patients with hormone receptor-positive breast cancer. The purpose of this study was to investigate the accuracy of post-chemotherapy biological markers for predicting the recovery of ovarian function in breast cancer patients of the ASTRRA trial, with chemotherapy-induced amenorrhoea. Using data of 82 participants from a single institution in the ASTRRA trial, the post-chemotherapy serum levels of the anti-Müllerian hormone (AMH), oestradiol, inhibin B and other clinical factors associated with chemotherapy-induced amenorrhoea were evaluated...
August 1, 2018: Endocrine Connections
Mariam Imnadze Miller, Andrew Feifer, Darren R Feldman, Brett S Carver, George J Bosl, Robert J Motzer, Dean F Bajorin, Joel Sheinfeld
OBJECTIVE: To characterize clinical and pathologic outcomes of cisplatin-refractory or relapsed germ cell tumor (GCT) patients who underwent retroperitoneal lymph node dissection (RPLND) following salvage chemotherapy with either conventional or high dose regimens. METHODS: Data was reviewed to identify all patients treated with TIP or TICE salvage chemotherapy between 1994 and 2011(n=184) at our institution. We report clinicopathologic and outcomes data on 131 patients who were further managed with surgical resection...
October 5, 2018: Urology
Raúl A Montañez-Valverde, David Hurtado-de-Mendoza, Arturo Loaiza-Bonilla
Endothelial biomarkers are gaining interest in the stratification of cardiovascular risk and early diagnosis of cardiotoxicity secondary to antineoplastic drugs. Interestingly, some drugs, such as anthracyclines, have been recently associated with vascular damage, which reveals the pivotal role of research in identifying biomarkers that could potentially be included into more specific cardiotoxicity risk scores. An extensive report of the incidences of cardiovascular adverse effects of oncologic drugs is presented, with the main purpose of highlighting not only the risk of developing heart failure but also the importance of associated vascular adverse effects (i...
July 18, 2018: Curēus
Kelly R McMahon, Maya Harel-Sterling, Michael Pizzi, Louis Huynh, Erin Hessey, Michael Zappitelli
BACKGROUND: Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities. Few studies have comprehensively evaluated kidney outcomes and 24-h ambulatory BP monitoring (ABPM) in this population. We aimed to describe chemotherapy-associated acute kidney injury (AKI) and late kidney outcomes using standardized definitions. METHODS: This was a single-center longitudinal pilot study of 23 children who participated in a previous study during cisplatin, carboplatin, or ifosfamide treatment...
September 14, 2018: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
Oliver Ng, Barrie Keeler, John Alastair Simpson, Srinivasan Madhusudan, Matthew Brookes, Austin Acheson
BACKGROUND: Anemia is common with esophagogastric adenocarcinoma, increasing mortality, blood transfusions, and reducing quality of life (QOL). No clear evidence exists for safe and effective treatment. METHODS: Anemic patients (Hb <12 g/dl women, <13 g/dl men) with esophagogastric adenocarcinoma were recruited before initiation of palliative chemotherapy. Patients were randomized to standard care or single dose of intravenous iron isomaltoside (IVI) before chemotherapy...
September 10, 2018: Nutrition and Cancer
Scott C Johnson, Zachary L Smith, Charles Nottingham, Zeyad R Schwen, Stephen Thomas, Elliot Fishman, Nam Ju Lee, Philip M Pierorazio, Scott E Eggener
OBJECTIVE: To evaluate whether specific clinical or radiographic factors predict inferior vena cava (IVC) or abdominal aortic (AA) resection or reconstruction (RoR) at the time of post-chemotherapy retroperitoneal lymph node dissection (RPLND) for germ cell tumors of the testicle. MATERIALS & METHODS: 277 patients undergoing post-chemotherapy RPLND at two institutions between 2005-2015 were identified. Preoperative imaging was reviewed with radiologists blinded to operative details...
September 1, 2018: Urology
Difan Zheng, Yiyang Wang, Yuan Li, Yihua Sun, Haiquan Chen
Background: Recently, nomogram has been widely used in cancer prognoses. However, the predicting model for post-chemotherapy patients with resected IIIA non-small cell lung cancer (NSCLC) still remains scarce. Here, we tried to develop nomograms for predicting the recurrence and survival of these patients. Methods: We retrospectively analyzed our database from October 2007 to May 2013 at Fudan University Shanghai Cancer Center. 437 qualified patients were included...
July 2018: Journal of Thoracic Disease
Jennifer S Gewandter, Jenna Chaudari, Chinazom Ibegbu, Rachel Kitt, Jennifer Serventi, Joy Burke, Eva Culakova, Noah Kolb, Kathleen A Sluka, Mohamedtaki A Tejani, Nimish A Mohile
Chemotherapy-induced peripheral neuropathy (CIPN) occurs in approximately 68% of patients who receive neurotoxic chemotherapy and lasts at least 6 months post-chemotherapy in approximately 30% of individuals. CIPN is associated with decreased quality of life and functional impairments. Evidence suggests that CIPN symptoms are caused, in part, by enhanced excitability and impaired inhibition in the central nervous system. Transcutaneous electrical nerve stimulation (TENS) decreases pain by counteracting both of these mechanisms and is efficacious in other conditions associated with neuropathic pain...
August 27, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Yen-Hao Chen, Hung-I Lu, Chien-Ming Lo, Yu-Ming Wang, Shang-Yu Chou, Chang-Chun Hsiao, Chao-Cheng Huang, Li-Hsueh Shih, Su-Wei Chen, Shau-Hsuan Li
BACKGROUND: To evaluate the role of blood vascular endothelial growth factor (VEGF) kinetics in patients with locally advanced esophageal squamous cell carcinoma (ESCC) receiving curative concurrent chemoradiotherapy (CCRT). METHODS: A total of 97 locally advanced ESCC patients were enrolled. All the patients had their blood drawn at three time points to determine their levels of VEGF, including pre-chemotherapy (day 0), post-chemotherapy (day 5), and pre-cycle 2 chemotherapy (day 28)...
August 20, 2018: BMC Cancer
F Honecker, J Aparicio, D Berney, J Beyer, C Bokemeyer, R Cathomas, N Clarke, G Cohn-Cedermark, G Daugaard, K-P Dieckmann, K Fizazi, S Fosså, J R Germa-Lluch, P Giannatempo, J A Gietema, S Gillessen, H S Haugnes, A Heidenreich, K Hemminki, R Huddart, M A S Jewett, F Joly, J Lauritsen, A Lorch, A Necchi, N Nicolai, C Oing, J Oldenburg, D Ondruš, A Papachristofilou, T Powles, A Sohaib, O Ståhl, T Tandstad, G Toner, A Horwich
The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the diagnosis and treatment of testicular cancer (34 panel members attended the conference; an additional two panel members [CB and K-PD] participated in all preparatory work and subsequent manuscript development). The aim of the conference was to develop detailed recommendations on topics relating to testicular cancer that are not covered in detail in the current ESMO Clinical Practice Guidelines (CPGs) and where the available level of evidence is insufficient...
August 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Astha Koolwal Kapoor, Sushma Bhatnagar
Suicide risk is very high in the patients suffering from advanced cancer. Around 60% of patients with advanced cancer suffer from cancer related pain and this further accentuates the risk of psychiatric disorders as well as suicide. A fifty year old male who was a known case of carcinoma of floor of mouth, post chemotherapy and post radiotherapy came in the outpatient clinic with complains of throat pain which increased on swallowing. On further probing, it was revealed, that he consumed poison in the recent past while being agitated and upset with the severe throat pain...
July 2018: Indian Journal of Palliative Care
Isabel Rauscher, Matthias Eiber, Wolfgang A Weber, Jürgen E Gschwend, Thomas Horn, Tobias Maurer
Positron-emission tomography/computed tomography combining both functional and morphological information has emerged as a powerful tool in oncological imaging within the past decades. The most commonly used radiotracer in oncology visualizing metabolic information is 2-[18F]fluoro-2-deoxy-d-glucose. However, the use of 2-[18F]fluoro-2-deoxy-d-glucose in urological oncology is challenging, as it is limited by physiological excretion through the urinary system. Therefore, it is only useful when applied to specific indications in selected patients with urological malignancy; for example, for detection of residual disease in the post-chemotherapy management of patients with seminoma...
August 13, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
Ming Liu, Julia Y S Tsang, Michelle Lee, Yun-Bi Ni, Siu-Ki Chan, Sai-Yin Cheung, Jintao Hu, Hong Hu, Gary M K Tse
AIMS: In breast cancer models, the functional roles of CD147 in proliferation, invasion and treatment resistance have been widely reported. However, there are only a few studies examining the clinicopathological correlation and prognostic relevance of CD147 in breast cancer, especially in relation to breast cancer molecular subtypes. METHODS: In this study, we analysed CD147 expression in a large cohort of breast cancers, correlating with clinicopathological features and the expression of a comprehensive panel of biomarkers in triple-negative breast cancer (TNBC) and non-TNBC subsets...
August 11, 2018: Journal of Clinical Pathology
John Eckstrom, Trace Bartels, Ivo Abraham, Hitendra Patel, Emad Elquza, Aaron J Scott, Steven Malangone, Jerrelee Hollings, Ali McBride
BACKGROUND: Practice patterns of same-day versus next-day pegfilgrastim vary in numerous practice settings across the country. Current utilization with same-day pegfilgrastim reduced overall visits and reduced treatment time for chemotherapy administration. OBJECTIVE: To assess the efficacy and safety of same-day versus next-day pegfilgrastim in patients with colorectal cancer. METHODS: Patient data was extracted through electronic health records (EHR) search of ICD-9 codes that matched patients with CRC and treated with FOLFOX or FOLFIRI from November 2013 to January 2016...
August 8, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
N Sinha, J M Letourneau, K Wald, P Xiong, Tal Imbar, B Li, E Harris, E Mok-Lin, M I Cedars, Mitchell P Rosen
PURPOSE: After chemotherapy for breast cancer, most women will recover some ovarian function, but the timing and extent of this recovery are poorly understood. We studied post-chemotherapy ovarian recovery in women with and without a history of ovarian suppression during chemotherapy. METHODS: Reproductive age breast cancer patients who were seen prior to chemotherapy for fertility preservation consult were consented for follow-up ovarian function assessment (every 3-6 months after chemotherapy) with antral follicle count (AFC) in this prospective cohort study...
October 2018: Journal of Assisted Reproduction and Genetics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"